Brief: Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics And Disease Characteristics In Adults With Short Bowel Syndrome With Intestinal Failure (Sbs-If), According To New Stars Phase Iii Data From Ironwood At Acg 2024
28/10/2024 11:56
Oct 28 (Reuters) - Ironwood Pharmaceuticals Inc
IRWD.O :
* ONCE-WEEKLY APRAGLUTIDE SHOWED CONSISTENT TREATMENT EFFECT
ACROSS BASELINE DEMOGRAPHICS AND DISEASE CHARACTERISTICS IN
ADULTS WITH SHORT BOWEL SYNDROME WITH INTESTINAL FAILURE
(SBS-IF), ACCORDING TO NEW STARS PHASE III DATA FROM IRONWOOD AT
ACG 2024
* IRONWOOD: EXPECTS TO COMPLETE U.S. REGULATORY SUBMISSION
IN Q1
2025
Source text: ID:nBw8mZdtva
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation